1 September 2025 - The September 2025 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The September issue of the Schedule includes has a few new/revised listings of note: 

• Adalimumab (multiple) - restriction change
• Denosumab (Xgeva) - new formulation
• Dupilumab (Dupioxent) - new indication
• Dupilumab (Dupixent) - new formulation
• Ivacaftor (Kalydeco) - new indication
• Ruxolitinib phosphate (Jakavi) - new indication
• Palovaratene (Sohonos) - new medicine
• Secukinumab (Cosentyx) - new strength

Read summary of PBS changes